Biogen Inc. (FRA:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 16.40B |
| Revenue (ttm) | 8.51B |
| Net Income (ttm) | 1.30B |
| Shares Out | n/a |
| EPS (ttm) | 8.90 |
| PE Ratio | 12.58 |
| Forward PE | 8.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,014 |
| Average Volume | 153 |
| Open | 113.00 |
| Previous Close | 111.55 |
| Day's Range | 113.00 - 119.15 |
| 52-Week Range | 99.00 - 202.50 |
| Beta | n/a |
| RSI | 56.43 |
| Earnings Date | Jul 31, 2025 |
About Aspen Technology
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial StatementsNews
KalVista, Biogen, Ionis get EU positive opinions for key drugs
ZURZUVAE (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a posi...
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a posi...
Biogen Inc (BIIB) Announces Key Presentations at 2025 Alzheimer's Association International ...
Biogen Inc (BIIB) Announces Key Presentations at 2025 Alzheimer's Association International Conference | BIIB stock news
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), ta...
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing
Biogen Inc. (NASDAQ: BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP) . Biogen has invest...
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing
Biogen Inc. BIIB said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park (RTP).
Biogen to invest $2 billion more in North Carolina
Drugmaker Biogen said on Monday it will invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park.
Biogen to invest additional $2B in North Carolina’s Research Triangle Park
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolin...
US stocks close mixed, but near the lows for the day
The major U.S. stock indices closed mixed on the day. The Dow Jones Industrial Average and S&P 500 both ended lower, while the Nasdaq Composite rose, supported by gains in chip stocks. The Russell 200...
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the in...
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...
FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment
The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.’s (NYSE: LLY) Kisunla (donanemab-azbt) once-monthly amyl...
What's Driving the Market Sentiment Around Biogen?
Biogen's (NYSE: BIIB) short percent of float has fallen 10.75% since its last report. The company recently reported that it has 3.39 million shares sold short , which is 2.99% of all regular shares t...
Biogen sees negative Q2 impact from IPR&D, milestone expenses
Biogen starts phase 3 trial of felzartamab for kidney disease
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficac...
Biogen lauds benefits of higher dose Spinraza for spinal muscular atrophy
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected...
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Biogen Inc. (NASDAQ: BIIB) on Wednesday announced in a press release the topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for ...
Biogen’s salanersen shows promise in SMA, heads toward registrational trials
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense...
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Biogen said Wednesday its experimental treatment helped children with SMA even after they received an approved gene therapy from Novartis.
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being...